Western Blot: GPIHBP1 Antibody [NB110-41537] - Detection of Gpibph1 in transfected lysate (lane 1) & empty vector lysate was used as a negative control (Lane 2).
Immunocytochemistry/ Immunofluorescence: GPIHBP1 Antibody [NB110-41537] - Gpihbp1 antibody was tested in A431 cells with FITC (green). Nuclei and alpha-tubulin were counterstained with Dapi (blue) and Dylight 550 (red).
Mouse. Rat and Bovine reactivity reported in scientific literature (PMID: 24735886)
Alternate Names for GPIHBP1 Antibody
glycosylphosphatidylinositol anchored high density lipoprotein binding protein1
glycosylphosphatidylinositol-anchored high density lipoprotein-binding protein1
GPI anchored high density lipoprotein binding protein 1
GPI-anchored HDL-binding protein 1
High density lipoprotein-binding protein 1
GPIHBP1 (glycosylphosphatidylinositol-anchored HDL-binding protein 1) is a glycosylphosphatidylinositol-anchored glycoprotein of capillary endothelial cells that shuttle lipoprotein lipase (LPL) from the interstitial spaces to capillary lumen, and is essential for triglyceride-rich lipoproteins metabolism in mammalian plasma. GPIHBP1 is localized on luminal/abluminal capillary endothelial cell surfaces where it is bound by a glycosylphosphatidylinositol anchor and associates strongly with LPL. It serves as LPL transporter from sub-endothelial spaces to luminal face of capillaries, enabling lipolysis of circulating triglycerides localized within plasma chylomicrons. It has high affinity for HDL and binds to LPL, chylomicrons as well as APOA5. In the absence of GPIHBP1, the stores of catalytically active LPL within tissues are normal, but the LPL is mislocalized to interstitial spaces and is absent from capillary lumen. LPL mislocalization interferes with lipoprotein lipolysis and causes chylomicronemia. In humans, loss of function GPIHBP1 mutations leads to familial chylomicronemia. It binds LPL and apoA-V strongly for serving as a platform for lipolysis within capillaries, particularly in tissues which show high expression levels for both GPIHBP1 and LPL genes, such as heart, skeletal muscle and adipose tissue. Gpihbp1-/Gpihbp1- knock out mice have shown that GPIHBP1-deficiency causes severe hypertriglyceridemia.
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.